Strong Biosimilar Performance Increases Market Share, Decreases Prices, Report Says

Biosimilar sales appear generally strong, despite market struggles for Hadlima, Samsung Bioepis’ biosimilar challenger for AbbVie’s Humira (adalimumab), and other Humira challengers, according to the company’s first quarter biosimilar market report.
Source: Drug Industry Daily